GleamWall
中文EN

KROS Keros Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1664710 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-83.4%
TTM net income YoY-195.8%
TTM EPS YoY-248.7%
Revenue 3-yr CAGR1,616.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-181.3%
Net margin-152.7%
FCF margin-119.4%
EBITDA margin-177.3%

Returns

ROE-12.6%
ROA-11.8%
ROIC (approx.)-389.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio18.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$40.01M$0$32,000$380,000$14.12M$18.17M$211.19M$0
R&D expense$20.49M$22.33M$16.10M$17.91M$19.52M$43.50M$48.71M$45.63M
SG&A expense$6.70M$8.61M$10.15M$11.74M$10.13M$14.48M$10.50M$10.66M
Operating income$12.82M-$30.94M-$25.88M-$29.27M-$15.38M-$39.82M$152.04M-$53.25M
Pretax income$14.93M-$28.71M-$23.71M-$24.98M-$8.70M-$32.92M$158.49M-$45.73M
Income tax$772,000$0$0-$1.51M-$1.42M-$2.22M$10.04M$300,000
Net income$14.15M-$28.71M-$23.71M-$23.46M-$7.28M-$30.70M$148.45M-$46.03M
EBITDA$13.20M-$30.54M-$25.47M-$28.87M-$14.99M-$39.45M$152.38M-$52.92M
EPS (basic)0.71-1.45-1.21—-0.18-0.763.66—
EPS (diluted)0.70-1.45-1.21—-0.18-0.763.62—
Weighted avg. shares (diluted)20.34M19.80M19.63M—40.62M40.61M41.02M—
Balance sheet
Cash & equivalents$259.46M$257.61M$281.50M$287.42M$693.47M$690.22M$720.54M$561.38M
Receivables$20.00M$0$400,000$3.57M$3.49M$15.82M$17.29M$2.74M
Current assets$287.63M$266.88M$290.68M$315.43M$719.31M$732.81M$759.51M$588.89M
PP&E, net$3.39M$3.71M$3.96M$4.30M$4.56M$4.84M$4.47M$4.24M
Total assets$307.37M$287.60M$312.29M$338.02M$742.78M$757.16M$784.56M$615.89M
Current liabilities$15.86M$12.15M$12.85M$20.41M$24.09M$34.71M$39.38M$27.45M
Total liabilities$28.27M$25.28M$26.66M$34.89M$39.20M$50.43M$55.69M$44.33M
Shareholders' equity$279.10M$262.32M$285.63M$303.13M$703.58M$706.73M$728.87M$571.55M
Shares outstanding19.83M19.83M19.73M19.54M40.63M40.62M40.56M40.55M
Cash flow statement
Operating cash flow$3.39M-$20.42M-$3.53M-$27.29M$3.25M-$29.62M$161.17M-$46.01M
Capital expenditure$59,000$155,000$73,000$134,000$132,000$720,000$565,000$289,000
Free cash flow$3.33M-$20.58M-$3.60M-$27.43M$3.12M-$30.34M$160.61M-$46.30M
Investing cash flow-$59,000-$155,000-$73,000-$134,000-$132,000-$720,000-$565,000-$289,000
Financing cash flow-$1.47M-$3.31M-$2.32M-$378.63M$140,000$17,000$4,000$75.54M
Depreciation & amortization$384,000$402,000$403,000$400,000$395,000$370,000$344,000$332,000
Stock-based compensation$4.20M$5.38M$6.20M$7.30M$3.99M$8.54M$8.86M$9.20M
Share buybacks———$375.00M————

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.